US EditionAdcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025
- Adcentrx Therapeutics presents first clinical data for ADRX-0706 at the 2025 ASCO Annual Meeting in Chicago.
- The company develops ADRX-0706, a clinical-stage Nectin-4 antibody-drug conjugate.
- This includes interim results from the Phase 1a dose escalation trial NCT06036121.
- Adcentrx will present the data as a poster, Abstract Number 3018, from May 30 to June 3, 2025.
- The preliminary findings support the drug's differentiated safety, PK, and efficacy profile.
Insights by Ground AI
Does this summary seem wrong?
27 Articles
27 Articles
All
Left
1
Center
11
Right
Hanford Sentinel+26 Reposted by 26 other sources
Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025
Interim results from Phase 1a dose escalation to be presentedData provide clinical proof of concept for Adcentrx's novel technology platform; highlight unique opportunity for ADRX-0706 to address significant unmet needs for patients with limited therapeutic options
Coverage Details
Total News Sources27
Leaning Left1Leaning Right0Center11Last UpdatedBias Distribution92% Center
Bias Distribution
- 92% of the sources are Center
92% Center
C 92%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage